Concepedia

Jude Canon

JC

37

Publications

7.3K

Citations

31

H-Index

1996

Active since

Affiliations

Amgen (United States)(Current)

University of California, Los Angeles

Harvard University

City of Hope

Peter MacCallum Cancer Centre

Jude Canon is an author at Amgen (United States) specializing in medicine, cell biology, and radiation oncology.

Top concepts

Publications per year

1996–2023

37

Publications

37

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

Jude Canon, Karen Rex, Anne Y. Saiki et al. · Nature · 2019 · 2.2K citations

, , +5

KRAS <sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid Tumors

David S. Hong, Marwan Fakih, John H. Strickler et al. · New England Journal of Medicine · 2020 · 1.6K citations · Full text

Discovery of a Covalent Inhibitor of KRAS<sup>G12C</sup> (AMG 510) for the Treatment of Solid Tumors

Brian A. Lanman, Jennifer R. Allen, John G. Allen et al. · Journal of Medicinal Chemistry · 2019 · 677 citations · Full text

, , +20

AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies

Sean Caenepeel, Sean P. Brown, Brian Belmontes et al. · Cancer Discovery · 2018 · 408 citations · Full text

Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development

Daqing Sun, Zhihong Li, Yosup Rew et al. · Journal of Medicinal Chemistry · 2014 · 290 citations · Full text

Rows per page

1–5 of 37